Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer

• Main Authors: Marra Jai Aghajani, Tao Yang, Ulf Schmitz, Alexander James, Charles Eugenio McCafferty, Paul de Souza, Navin Niles, Tara L Roberts
• Format: Article
• Language: English
• Published: Bioscientifica 2020-10-01
• Series: Endocrine Connections
• Subjects: thyroid cancer; epithelial-to-mesenchymal transition; programmed cell death-ligand 1; cd8; survival
• Online Access: https://ec.bioscientifica.com/view/journals/ec/9/10/EC-20-0268.xml
• ISSN: 2049-3614; 2049-3614

Programmed cell death-ligand 1 (PD-L1) has recently been shown to play a role in the regulation of epithelial-to-mesenchymal transition (EMT); however, the relationship between PD-L1 expression, EMT and the inflammatory tumour microenvironment has yet to be investigated in thyroid cancer. To address this issue, we examined the expression of CD8, PD-L1 and the EMT markers E-cadherin and vimentin in a cohort of 74 papillary thyroid cancer (PTC) patients and investigated the association of these with clinicopathologic characteristics and disease-free survival (DFS). The relationship between PD-L1 and EMT was further examined in three thyroid cancer cell lines via Western blot and live cell imaging. In order to expand our in vitro findings, the normalise d gene expression profiles of 516 thyroid cancer patients were retrieved and analysed from The Cancer Genome Atlas (TCGA). PD-L1 positivity was significantly higher in PTC patients exhibiting a mesenchymal phenotype (P = 0.012). Kaplan–Meier analysis revealed that PD-L1 (P = 0.045), CD8 (P = 0.038) and EMT status (P = 0.038) were all significant predictors for DFS. Sub-analysis confirmed that the poorest DFS was evident in PD-L1 positive patients with EMT features and negative CD8 expression (P < 0.0001). IFN-γ treatment induced upregulation of PD-L1 and significantly promoted an EMT phenotype in two thyroid cancer cell lines. Our findings suggest that PD-L1 signalling may play a role in stimulating EMT in thyroid cancer. EMT, CD8 and PD-L1 expression may serve as valuable predictive biomarkers in patients with PTC.